VR Adviser’s Tenax Therapeutics TENX Stock Holding History

VR Adviser’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.8M	Buy	+1,675,262	New	+$22.7M	1%	23
2025 Q4	–	Sell	-437,708	Closed	-$3.33M	–	32
2025 Q3	$3.33M	Buy	437,708 +339,144	+344%	+$2.07M	0.19%	32
2025 Q2	$568K	Sell	98,564 -109,769	-53%	-$634K	0.04%	31
2025 Q1	$1.36M	Hold	208,333	–	–	0.12%	32
2024 Q4	$1.29M	Hold	208,333	–	–	0.09%	35
2024 Q3	$721K	Buy	+208,333	New	+$755K	0.04%	38

Other funds holding TENX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser's TENX Position: Q1 2026 in Review

VR Adviser opened a new position in Tenax Therapeutics (TENX) in Q1 2026: 1,675,262 shares worth $26.8M. The stake represents 1% of the portfolio and ranks #23 among its holdings. This is a return to the name: VR Adviser previously reported a position in TENX as recently as Q3 2025.

VR Adviser first reported a position in TENX in Q3 2024 and has held it in 6 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

VR Adviser held 1,675,262 shares of Tenax Therapeutics worth $26.8M as of Q1 2026.
Tenax Therapeutics was a new VR Adviser position in Q1 2026.
Tenax Therapeutics made up 1% of VR Adviser's portfolio in Q1 2026, its #23 holding.
VR Adviser first reported a position in Tenax Therapeutics in Q3 2024 and has held it in 6 quarters since.
80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.